La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Nova Eye Medical Croissance future
Future contrôle des critères 2/6
Nova Eye Medical is forecast to grow earnings and revenue by 91.7% and 33.5% per annum respectively. EPS is expected to grow by 94.8% per annum. Return on equity is forecast to be -9.4% in 3 years.
Informations clés
91.7%
Taux de croissance des bénéfices
94.8%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 16.0% |
| Taux de croissance des recettes | 33.5% |
| Rendement futur des capitaux propres | -9.4% |
| Couverture par les analystes | Low |
| Dernière mise à jour | 11 Jul 2024 |
Mises à jour récentes de la croissance future
Recent updates
Take Care Before Diving Into The Deep End On Nova Eye Medical Limited (ASX:EYE)
Aug 06
Nova Eye Medical Limited (ASX:EYE) Soars 29% But It's A Story Of Risk Vs Reward
Apr 18Is There An Opportunity With Nova Eye Medical Limited's (ASX:EYE) 43% Undervaluation?
Mar 26News Flash: Analysts Just Made A Captivating Upgrade To Their Nova Eye Medical Limited (ASX:EYE) Forecasts
Jan 19Further Upside For Nova Eye Medical Limited (ASX:EYE) Shares Could Introduce Price Risks After 38% Bounce
Dec 27We're Not Very Worried About Nova Eye Medical's (ASX:EYE) Cash Burn Rate
Sep 03Improved Revenues Required Before Nova Eye Medical Limited (ASX:EYE) Stock's 43% Jump Looks Justified
Apr 17Is Nova Eye Medical (ASX:EYE) In A Good Position To Invest In Growth?
Dec 16We Think Nova Eye Medical (ASX:EYE) Needs To Drive Business Growth Carefully
Aug 27Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 6/30/2026 | 43 | 3 | 2 | 4 | 2 |
| 6/30/2025 | 32 | -3 | -4 | -2 | 2 |
| 6/30/2024 | 22 | -8 | -8 | -7 | 2 |
| 12/31/2023 | 19 | -14 | -7 | -6 | N/A |
| 9/30/2023 | 18 | -15 | -7 | -7 | N/A |
| 6/30/2023 | 17 | -15 | -8 | -7 | N/A |
| 3/31/2023 | 16 | -13 | -9 | -8 | N/A |
| 12/31/2022 | 15 | -11 | -10 | -9 | N/A |
| 9/30/2022 | 14 | -9 | -10 | -7 | N/A |
| 6/30/2022 | 13 | -7 | -10 | -5 | N/A |
| 3/31/2022 | 13 | -7 | -13 | -8 | N/A |
| 12/31/2021 | 13 | -6 | -16 | -11 | N/A |
| 9/30/2021 | 13 | -5 | -16 | -12 | N/A |
| 6/30/2021 | 13 | -4 | -15 | -13 | N/A |
| 12/31/2020 | 12 | -9 | -1 | 0 | N/A |
| 9/30/2020 | 13 | -10 | 2 | 3 | N/A |
| 6/30/2020 | 13 | -10 | 4 | 5 | N/A |
| 12/31/2019 | 16 | -6 | -4 | -1 | N/A |
| 9/30/2019 | 16 | -6 | -6 | -2 | N/A |
| 6/30/2019 | 16 | -7 | -8 | -4 | N/A |
| 3/31/2019 | 48 | -7 | -7 | -2 | N/A |
| 12/31/2018 | 49 | -6 | -6 | -1 | N/A |
| 9/30/2018 | 64 | -6 | -6 | 0 | N/A |
| 6/30/2018 | 79 | -5 | -6 | 1 | N/A |
| 3/31/2018 | 77 | -5 | -9 | -2 | N/A |
| 12/31/2017 | 75 | -5 | -13 | -4 | N/A |
| 9/30/2017 | 73 | -3 | N/A | -4 | N/A |
| 6/30/2017 | 72 | -1 | N/A | -3 | N/A |
| 3/31/2017 | 72 | 1 | N/A | -1 | N/A |
| 12/31/2016 | 73 | 3 | N/A | 2 | N/A |
| 9/30/2016 | 73 | 3 | N/A | 3 | N/A |
| 6/30/2016 | 73 | 3 | N/A | 5 | N/A |
| 3/31/2016 | 70 | 3 | N/A | 6 | N/A |
| 12/31/2015 | 67 | 2 | N/A | 7 | N/A |
| 9/30/2015 | 65 | 2 | N/A | 7 | N/A |
| 6/30/2015 | 63 | 2 | N/A | 7 | N/A |
| 3/31/2015 | 61 | 1 | N/A | 5 | N/A |
| 12/31/2014 | 59 | 1 | N/A | 4 | N/A |
| 9/30/2014 | 57 | 1 | N/A | 3 | N/A |
| 6/30/2014 | 54 | 1 | N/A | 3 | N/A |
| 3/31/2014 | 51 | 0 | N/A | 2 | N/A |
| 12/31/2013 | 47 | -1 | N/A | 2 | N/A |
| 9/30/2013 | 45 | -1 | N/A | 2 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: EYE is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: EYE is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: EYE is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: EYE's revenue (33.5% per year) is forecast to grow faster than the Australian market (5.4% per year).
Croissance élevée des revenus: EYE's revenue (33.5% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: EYE is forecast to be unprofitable in 3 years.